Summary

Patients will be registered prior to, during or at the completion of neoadjuvant
chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1
every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant
chemotherapy will not be eligible for iCRS and will be removed from the study.

Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS)
will be performed in the usual fashion in both arms. Patients will be randomized at the
time of iCRS (iCRS must achieve no gross residual disease or no disease >1.0 cm in
largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC (Arm A) will
receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After
postoperative recovery patients will receive standard post-operative platinum-based
combination chemotherapy. Patients randomized to surgery only (Arm B) will receive
postoperative standard chemotherapy after recovery from surgery.

Both groups will receive an additional 2-3 cycles of platinum-based combination
chemotherapy per institutional standard (Paclitaxel 175 mg/m2 IV over 3 hours and
Carboplatin AUC 6 IV on Day 1 every 21 days for 2-3 cycles) for a maximum total of 6
cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib
individualized dosing until progression or 36 months (if no evidence of disease).

Eligibility

1. Patients must have a pathologic diagnosis of high grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage III or IV documented on CT scan/MRI, must be recommended to undergo neoadjuvant chemotherapy (3-4 cycles allowed) and are considered candidates for interval cytoreductive surgery (iCRS) as determined by the enrolling investigator.
2. Patients with stage IV disease must have complete response of extra-abdominal disease on preoperative imaging (e.g. pleural effusion, mediastinal, inguinal, supraclavicular lymphadenopathy, or other extra-abdominal metastases).
3. Patient must have no gross residual disease or no disease >1.0 cm in largest diameter following iCRS and prior to randomization.
4. Patients must have Myriad myChoice HRD test results available prior to registration.
5. Patient must have adequate bone marrow and organ function: Bone marrow function: Hemoglobin = 8.5 g/dL. Absolute neutrophil count (ANC) = 1,000/mm3. Platelets = 100,000/mm3. Renal function: Creatinine = 1.3mg/dl Calculated creatinine clearance (= 30 mL/min/1.73 m2) per National Kidney Foundation guidelines and NHANES III Hepatic function: Bilirubin = 1.5 times ULN. ALT = 3 times the ULN. AST = 3 times the ULN. Neurologic function: Peripheral neuropathy = CTC AE grade 2. Blood coagulation parameters: PT with an INR of = 1.5 and a PTT = 1.5 times the ULN. For patients on full-dose oral anti-coagulation (such as warfarin or rivaroxaban), in-range INR (usually between 2 and 3) and a PTT <1.2 times the ULN.
6. Patients must have a GOG performance status of 0 or 1.
7. Patient must be age > 18.
8. Patients must have a life expectancy > 3 months.
9. Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to iCRS and must be practicing an effective form of contraception (with failure rate <1% per year) during the study period and for 6 months following the last dose of niraparib. Patients of childbearing potential must consent to pregnancy testing prior to receiving niraparib and monthly thereafter for the duration of the study. Patients are considered postmenopausal and not of child-bearing potential if they are free from menses for >1 year or are surgically sterilized.
10. Patients must have normal blood pressure (BP) or adequately treated and controlled hypertension based on local standard of care (systolic BP < 140 mmHg and diastolic < 90 mmHg)
11. Patients receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to randomization.
12. Patients must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
13. Patients with known human immunodeficiency virus (HIV) are allowed if they meet all of the following criteria:
14. Cluster of differentiation 4 =350/µL and viral load <400 copies/mL
15. No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months prior to randomization
16. No history of HIV associated malignancy for the past 5 years
17. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started >4 weeks prior to randomization.

Treatment Sites in Georgia